New eye injection could reduce treatment frequency for wet AMD

NCT ID NCT07587515

Recruiting now Disease control Sponsor: Eyconis INC. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 4 times

Summary

This early-stage trial tests a new medicine called EYC-0305, given as an eye injection every 24 weeks, in 30 people aged 50 and older with wet age-related macular degeneration (AMD). The main goal is to check if the treatment is safe and tolerable. Researchers will also measure how the drug moves in the body and whether it helps control disease activity and vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Bellaire, TX
RECRUITING

Bellaire, Texas, 77401, United States
Beverly Hills, CA
RECRUITING

Beverly Hills, California, 90211, United States
Erie, PA
RECRUITING

Erie, Pennsylvania, 16505, United States
McAllen, TX
RECRUITING

McAllen, Texas, 78503, United States
The Woodlands, TX
RECRUITING

The Woodlands, Texas, 77384, United States
Wake Forest, NC
RECRUITING

Wake Forest, North Carolina, 27587, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.